Scilex Holding Company

NASDAQ:SCLX

Drug Manufacturers - General

Healthcare
$6.34 -2.38%

-$0.17 today

Market cap
$53.83M
Beta
1.71
P/E (TTM)
-0.1
EPS (TTM)
-$60.90
52W Low $2.62High $21.34

Volume 0.00M

Average 0.13M

SCLX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Scilex Holding CompanyNASDAQ: SCLX

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares dips below year-ago levels

Q1 FY2026 weighted avg shares of 6.89M shares fell 40.4% year over year, behind the +60.8% change in trailing-twelve-month weighted avg shares. Sequentially, it fell 37.5% from the prior quarter. Over 3 fiscal years it compounded at +42.2% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -40.4% toward the trailing-twelve-month pace of +60.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
6.89M-37.5% QoQ
Last fiscal yearDec 2025
11.03M+58.7% YoY
LTMMar 2026
10.28M+60.8% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-40.4%——
1 year+58.7%——
3-year CAGR+42.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
11.03M USD
Year-over-year change
+58.7%
4-year CAGR
+30.6%

Weighted Avg Shares vs competitors

How SCLX compares with its peers on the latest reported figures

  • SCLX's LTM Mar 2026 weighted avg shares of 10.28M shares is the lowest of the 9 companies compared; the peer median is 93.88M shares.
  • Its year-over-year change of +60.8% is the 4th highest of 9, against a peer median of +34.8%.
  • Over three fiscal years its annual growth of +42.2% compares with a peer median of +21.3%.
SCLX Competitors Peer median
Weighted Avg Shares for SCLX and competitors
Company Period LTM YoY 3-year CAGR
IRDOpus Genetics, Inc.LTM Mar 2026406.29M +1283.9%+214.9%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026312.72M +1040.7%+186.8%
ALECAlector, Inc.LTM Mar 2026104.14M +6.5%+7.7%
LUCDLucid Diagnostics Inc.LTM Mar 2026102.76M +82.6%+41.3%
CTORCitius Oncology, Inc.LTM Mar 202685M +20.9%-6.7%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 202661.23M +1.8%+14.3%
SEERSeer, Inc.LTM Mar 202656.96M -7.5%-2.7%
AGENAgenus Inc.LTM Mar 202633.32M +48.8%+28.3%
SCLXScilex Holding CompanyLTM Mar 202610.28M +60.8%+42.2%
Peer median (excluding SCLX) 93.88M+34.8%+21.3%

Competitors are the stored peer set for SCLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue31.32M38.03M46.74M56.59M30.25M
Cost of Revenue3.63M10.8M15.68M16.69M15.22M
Gross Profit27.68M27.24M31.06M39.9M15.03M
Gross Margin88.4%71.6%66.5%70.5%49.7%
Research & Development9.2M9.05M12.75M9.64M20.71M
Selling, General & Admin50.58M64.9M119.64M119.02M266.63M
Operating Expenses63.52M77.87M136.49M123.3M287.34M
Depreciation & Amortization3.78M4.45M4.15M4.05M4.62M
EBITDA(72.88M)(9.3M)(109.1M)(66.8M)(357.95M)
EBITDA Margin-232.7%-24.5%-233.4%-118.0%-1183.2%
Operating Income(35.84M)(50.63M)(105.43M)(83.4M)(272.3M)
Operating Margin-114.4%-133.1%-225.6%-147.4%-900.1%
Interest Income00000
Interest Expense11.76M9.6M1.07M1.96M11.46M
Other Income / Expenses(52.58M)27.27M(8.89M)10.59M(101.72M)
Income Before Tax(88.42M)(23.36M)(114.32M)(72.81M)(374.03M)
Pre-Tax Margin-282.3%-61.4%-244.6%-128.7%-1236.3%
Income Tax Expense5K4K13K(1K)26K
Net Income(88.42M)(23.36M)(114.33M)(72.81M)(358.73M)
Net Margin-282.4%-61.4%-244.6%-128.7%-1185.8%
EPS (Basic)(23.29)(6.09)(44.85)(19.43)(36.48)
EPS (Diluted)(23.29)(6.09)(44.85)(19.43)(36.48)
Weighted Avg Shares3.8M3.83M3.72M6.95M11.03M
Weighted Avg Shares (Diluted)3.8M3.83M3.72M6.95M11.03M

Scilex Holding Company

NASDAQ:SCLX

Intrinsic Alpha fair value

Locked

Current Price

$6.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.